Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Sponsor: Rapport Therapeutics Inc.
Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Official title: An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-12-15
Completion Date
2028-02-03
Last Updated
2026-01-23
Healthy Volunteers
No
Interventions
RAP-219
Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.
Locations (7)
Consultants in Epilepsy and Neurology, PLLC
Boise, Idaho, United States
Mayo Clinic
Rochester, Minnesota, United States
NYU Langone Comprehensive Epilepsy Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Pennsylvania - Department of Neurology
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States